$1.15
0[0.00%]
At close: Apr 26
$1.15
0[0.00%]
PreMarket: 4:20PM EDT
Protalix BioTherapeutics
(AMEX:PLX)Latest News for Protalix BioTherapeutics Stock (AMEX:PLX)
Protalix BioTherapeutics Stock (AMEX: PLX)
Categories: All
Thursday, March 14, 2024
Wednesday, March 13, 2024
Tuesday, November 14, 2023
Monday, November 06, 2023
Friday, November 03, 2023
Tuesday, October 31, 2023
Monday, October 23, 2023
Monday, October 09, 2023
Tuesday, September 12, 2023
Tuesday, August 08, 2023
Monday, August 07, 2023
- Protalix BioTherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga Newsdesk - Aug 7, 2023, 9:13AM
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga Insights - Aug 7, 2023, 9:05AM
- Protalix BioTherapeutics Q2 EPS $0.21 Beats $(0.04) Estimate, Sales $35.08M Beat $10.22M EstimateBenzinga Newsdesk - Aug 7, 2023, 6:55AM
- Earnings Scheduled For August 7, 2023Benzinga Insights - Aug 7, 2023, 4:12AM
Friday, August 04, 2023
Tuesday, May 23, 2023
Wednesday, May 10, 2023
- Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus TherapeuticsVandana Singh - May 10, 2023, 2:16PM
- Chiesi Global Rare Diseases, Protalix BioTherapeutics Announce FDA Approval Of ELFABRIO (pegunigalsidase alfa-iwxj) For Treatment Of Fabry DiseaseBenzinga Newsdesk - May 10, 2023, 6:05AM
Thursday, May 04, 2023
- Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To BrazilNabaparna Bhattacharya - May 4, 2023, 2:51PM
- Protalix Biotherapeutics And Chiesi Global Rare Diseases Get European Commission Approval Of Elfabrio (Pegunigalsidase Alfa) For The Treatment Of Fabry DiseaseHappy Mohamed - May 4, 2023, 10:35AM
- Protalix BioTherapeutics Q1 EPS $(0.05), Same YoY, Sales $9.58M Down From $16.09M YoYBenzinga Newsdesk - May 4, 2023, 6:53AM
- Earnings Scheduled For May 4, 2023Benzinga Insights - May 4, 2023, 6:34AM
Tuesday, February 28, 2023
Monday, February 27, 2023
- Why Lucira Health Shares Are Trading Higher By Over 228%; Here Are 20 Stocks Moving PremarketLisa Levin - Feb 27, 2023, 7:45AM
- Protalix Biotherapeutics Entered Into An At The Market Offering Agreement With H.C. Wainwright Under Which Protalix May Sell From Time To Time Common Stock Having An Aggregate Offering Price Of Up To $20MCharles Gross - Feb 27, 2023, 7:09AM
- Protalix BioTherapeutics FY EPS $(0.31) Beats $(0.39) Estimate, Sales $47.64M Beat $45.14M EstimateBenzinga Newsdesk - Feb 27, 2023, 6:34AM
- Earnings Scheduled For February 27, 2023Benzinga Insights - Feb 27, 2023, 4:46AM
Friday, February 24, 2023
- Earnings Preview For Protalix BioTherapeuticsBenzinga Insights - Feb 24, 2023, 2:02PM
- Chiesi Global Rare Diseases And Protalix BioTherapeutics Receive CHMP Opinion For Pegunigalsidase Alfa For Treatment Of Fabry Disease; European Commission Decision Anticipated In Beginning Of May 2023Happy Mohamed - Feb 24, 2023, 9:24AM
Friday, January 06, 2023
Friday, December 23, 2022
Tuesday, November 29, 2022
Monday, November 14, 2022
- Protalix BioTherapeutics Q3 EPS $(0.07) Up From $(0.09) YoY, Sales $14.18M Up From $12.05M YoYBenzinga Newsdesk - Nov 14, 2022, 6:52AM
- Protalix BioTherapeutics And Chiesi Global Rare Diseases Announce Resubmission Of Biologics License Application To FDA For Pegunigalsidase Alfa For The Treatment Of Fabry DiseaseBenzinga Newsdesk - Nov 14, 2022, 6:33AM
- Earnings Scheduled For November 14, 2022Benzinga Insights - Nov 14, 2022, 5:06AM